Case reports in oncology · 2025
Neurofibromatosis Type 1 with Relapsed/Refractory Precursor B-Lymphoblastic Lymphoma: Case Report and Literature Review.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Hongjuan, Leng Yanli, Gu Yan, Han Yan, Zhao Yuqi, Ding Guoyu, Wang Hongmei
Аннотация
INTRODUCTION: Concomitant occurrence of B-lymphoblastic lymphoma (B-LBL) and neurofibromatosis type 1 (NF1) is rare.
CASE PRESENTATION: We diagnosed and treated a child presenting with NF1 and relapsed B-LBL and reviewed the relevant literature through the last 8 years. Stage IV precursor B-LBL with central nervous system 3 was identified in this patient, with pain and activity abnormalities in both lower limbs. NF1 was diagnosed based on physical examination, brain magnetic resonance imaging, genetic testing, and family history. The patient relapsed after chemotherapy and was given blinatumomab. After 1 week of blinatumomab treatment, the lower limb pain was relieved. The child underwent umbilical cord blood transplantation after completing two sessions of blinatumomab therapy and is still disease-free to date.
CONCLUSION: The findings from this study will offer valuable empirical references for peers treating NF1 associated with refractory/relapsed B-LBL.
CASE PRESENTATION: We diagnosed and treated a child presenting with NF1 and relapsed B-LBL and reviewed the relevant literature through the last 8 years. Stage IV precursor B-LBL with central nervous system 3 was identified in this patient, with pain and activity abnormalities in both lower limbs. NF1 was diagnosed based on physical examination, brain magnetic resonance imaging, genetic testing, and family history. The patient relapsed after chemotherapy and was given blinatumomab. After 1 week of blinatumomab treatment, the lower limb pain was relieved. The child underwent umbilical cord blood transplantation after completing two sessions of blinatumomab therapy and is still disease-free to date.
CONCLUSION: The findings from this study will offer valuable empirical references for peers treating NF1 associated with refractory/relapsed B-LBL.